NCT01064466View on ClinicalTrials.gov

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

November 18, 2026

Study Completion Date

December 28, 2026

Conditions
Small Cell Lung Cancer
Interventions
DRUG

ETOPOSIDE - Usual

Etoposide Capsule

DRUG

ETOPOSIDE - Study

China Import Etoposide Capsule

Trial Locations (1)

20853

Medicine Invention Design, Inc. (MIDI) - IORG0007849 - NPI 1023387701, Rockville

All Listed Sponsors
collaborator

UnitedHealthcare

OTHER

lead

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

INDUSTRY